Physician profile
Timothy Drew Smith
NPI 1053750190
$1,542.86
in general payments reported to CMS, 2019-2025
23 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $174 · 2023: $501 · 2024: $318 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $228.81 | 2022-2025 | |
| Lilly USA, LLC | $180.34 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Viiv Healthcare Company | $137.91 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Corcept Therapeutics | $121.16 | 2022-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $109.02 | 2023-2025 | |
| Abbvie INC. | $104.29 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.11 | 2023-2025 | Jardiance, Synjardy |
| Amgen INC. | $87.34 | 2023-2024 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $84.37 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Xeris Pharmaceuticals, INC. | $63.00 | 2023-2025 | Gvoke Hypopen |
| Medtronic, INC. | $51.39 | 2025 | Minimed 780g |
| Paratek Pharmaceuticals, INC. | $51.37 | 2023-2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $30.19 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.09 | 2023-2025 | |
| Novo Nordisk INC | $29.11 | 2024-2025 | Ozempic, Rybelsus |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.60 | 2023 | Shingrix, Arexvy |
| Dexcom, INC. | $23.57 | 2025 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $19.85 | 2022 | |
| Insmed, INC. | $19.23 | 2024 | Arikayce |
| Boston Scientific Corporation | $17.41 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $13.94 | 2021 | |
| Cequr Corporation | $13.85 | 2024 | Cequr Simplicity |
| Exact Sciences Corporation | $12.91 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.